ERBB2 and Thrombocytopenia: Pooled analysis showed that compared to other anti-HER2 therapies, T-DM1 was associated with a significantly higher rate of fatigue, elevated ALT, elevated AST, and thrombocytopenia, but a significantly lower rate of diarrhea, vomiting, neutropenia, leucopenia, and febrile neutropenia (Table 2).